AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key franchises,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “With the breadth and performance of our business, I am optimistic for the future of AtriCure and look forward to sharing our pipeline and financial outlook at our Analyst and Investor Day in March.” Fourth Quarter 2024 Financial Results Revenue for the fourth quarter 2024 was $124.3 million, an increase of 16.6% (an increase of 16.7% on a constant currency basis) over fourth quarter 2023 revenue, reflecting growth across the business globally, partially offset by declines in our U.S. minimally invasive devices. U.S. revenue was $101.6 million, an increase of $12.8 million or 14.4%, compared to fourth quarter 2023 revenue. U.S. revenue growth was driven by sales of our cryoSPHERE® probes for pain management, AtriClip® Flex⋅V® devices in appendage management and the EnCompass® clamp in open ablation. International revenue increased $4.9 million or 27.7% (an increase of 28.1% on a constant currency basis) to $22.7 million, reflecting growth across all franchises and major geographic regions. Gross profit for the fourth quarter 2024 was $92.6 million compared to $79.8 million for the fourth quarter 2023. Gross margin was 74.5% and 74.9% for the fourth quarters 2024 and 2023, reflecting changes in product and geographic mix, as well as product costs. Loss from operations for the fourth quarter 2024 was $14.5 million, compared to $8.7 million for the fourth quarter 2023, driven by the $12 million payment for the acquisition of in-process research and development (IPR&D) included in research and development expenses. Basic and diluted net loss per share was $0.33 for the fourth quarter 2024, compared to $0.21 for the fourth quarter 2023. Adjusted EBITDA was positive for the fourth quarter 2024 at $12.7 million, compared to positive $4.8 million for fourth quarter of 2023. Adjusted loss per share for the fourth quarter 2024 was $0.08 compared to $0.21 for the fourth quarter 2023. Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release. 2024 Financial Results Revenue for 2024 was $465.3 million, an increase of $66.1 million or 16.5% as reported and on a constant currency basis, compared to 2023 revenue. Across all key product lines, our revenue grew as a result of deepening market penetration, continuing physician adoption and new product launches. U.S. revenue was $382.8 million, an increase of $49.3 million or 14.8%. International revenue was $82.5 million, an increase of $16.8 million or 25.6% as reported and on a constant currency basis. Gross profit for 2024 was $347.5 million compared to $300.4 million for 2023, and gross margin decreased to 74.7% for 2024 compared to 75.2% for 2023. Loss from operations for 2024 was $40.0 million, compared to $26.7 million for 2023, reflecting increased research and development costs related to new product introductions, clinical trials and acquired IPR&D related to our pulse-field ablation development program. Basic and diluted net loss per share was $0.95 for 2024, compared to $0.66 for 2023. Adjusted EBITDA was positive $31.1 million for 2024, compared to positive $19.4 million for 2023. The adjusted loss per share for 2024 was $0.67 compared to an adjusted loss per share of $0.75 for 2023. 2025 Financial Guidance Full year 2025 revenue is projected to be approximately $517 million to $527 million. Management now expects full year 2025 positive adjusted EBITDA of approximately $42 million to $44 million. Full year 2025 adjusted loss per share is expected to be in the range of $0.57 to $0.64. Additionally, management expects modest cash flow generation for the full year 2025. Conference Call AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter 2024 and full year 2024 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at https://ir.atricure.com/events-and-presentations/events. Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X @AtriCure. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory-related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 16, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. Use of Non-GAAP Financial Measures To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics. Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors. Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company’s core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” later in this release. Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release. Due to the nonrecurring nature of the fourth quarter 2024 asset acquisition, the Company has modified the calculation of adjusted EBITDA and adjusted loss per share to exclude acquired IPR&D expense reflecting the upfront cash payment for the exclusive licensing agreement and related future milestone payments. The Company believes it is now appropriate to modify the calculation of adjusted EBITDA and adjusted loss per share to exclude acquired IPR&D and milestone payments because the Company has concluded that such charges are not reflective of the operational results of the Company’s core business. The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business. ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, Except Per Share Amounts) (Unaudited) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 United States Revenue: Open ablation $ 32,986 $ 27,299 $ 123,647 $ 105,287 Minimally invasive ablation 10,474 12,677 45,737 44,577 Pain management 17,785 12,950 61,844 49,199 Appendage management 40,331 35,834 151,588 134,481 Total United States 101,576 88,760 382,816 333,544 International Revenue: Open ablation 9,014 8,468 34,693 31,483 Minimally invasive ablation 2,545 1,850 8,104 6,670 Pain management 1,856 799 5,624 2,013 Appendage management 9,286 6,666 34,070 25,535 Total International 22,701 17,783 82,491 65,701 Total revenue 124,277 106,543 465,307 399,245 Cost of revenue 31,658 26,728 117,783 98,875 Gross profit 92,619 79,815 347,524 300,370 Operating expenses: Research and development expenses 34,957 20,796 96,178 73,915 Selling, general and administrative expenses 72,185 67,687 291,359 253,138 Total operating expenses 107,142 88,483 387,537 327,053 Loss from operations (14,523 ) (8,668 ) (40,013 ) (26,683 ) Other expense, net (779 ) (748 ) (3,661 ) (3,164 ) Loss before income tax expense (15,302 ) (9,416 ) (43,674 ) (29,847 ) Income tax expense 266 373 1,024 591 Net loss $ (15,568 ) $ (9,789 ) $ (44,698 ) $ (30,438 ) Basic and diluted net loss per share $ (0.33 ) $ (0.21 ) $ (0.95 ) $ (0.66 ) Weighted average shares used in computing net loss per share: Basic and diluted 47,125 46,447 46,965 46,309 ATRICURE, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands) (Unaudited) December 31, 2024 December 31, 2023 Assets Current assets: Cash, cash equivalents, and short-term investments $ 122,721 $ 137,285 Accounts receivable, net 60,339 52,501 Inventories 75,335 67,897 Prepaid and other current assets 9,431 8,563 Total current assets 267,826 266,246 Property and equipment, net 41,659 42,435 Operating lease right-of-use assets 5,727 4,324 Goodwill and intangible assets, net 291,248 298,767 Other noncurrent assets 2,868 2,160 Total assets $ 609,328 $ 613,932 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $ 70,619 $ 72,036 Current lease liabilities 2,805 2,533 Total current liabilities 73,424 74,569 Long-term debt 61,865 60,593 Finance and operating lease liabilities 11,860 11,368 Other noncurrent liabilities 1,210 1,234 Total liabilities 148,359 147,764 Stockholders' equity: Common stock 49 48 Additional paid-in capital 863,710 824,170 Accumulated other comprehensive loss (1,035 ) (993 ) Accumulated deficit (401,755 ) (357,057 ) Total stockholders' equity 460,969 466,168 Total liabilities and stockholders' equity $ 609,328 $ 613,932 ATRICURE, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS (In Thousands) (Unaudited) Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA) Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net loss, as reported $ (15,568 ) $ (9,789 ) $ (44,698 ) $ (30,438 ) Income tax expense 266 373 1,024 591 Other income, net 779 748 3,661 3,164 Depreciation and amortization expense 4,826 4,179 18,733 14,813 Share-based compensation expense 10,385 9,312 40,405 35,728 Acquired in-process research & development 12,000 — 12,000 — Net gain from legal settlements — — — (4,412 ) Non-GAAP adjusted income (adjusted EBITDA) $ 12,688 $ 4,823 $ 31,125 $ 19,446 Reconciliation of Non-GAAP Adjusted Loss Per Share Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023 Net loss, as reported $ (15,568 ) $ (9,789 ) $ (44,698 ) $ (30,438 ) Loss on debt extinguishment — — 1,362 — Acquired in-process research & development 12,000 — 12,000 — Net gain from legal settlements — — — (4,412 ) Non-GAAP adjusted net loss $ (3,568 ) $ (9,789 ) $ (31,336 ) $ (34,850 ) Basic and diluted adjusted net loss per share $ (0.08 ) $ (0.21 ) $ (0.67 ) $ (0.75 ) Weighted average shares used in computing adjusted net loss per share Basic and diluted 47,125 46,447 46,965 46,309

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News